{
    "clinical_study": {
        "@rank": "23361", 
        "arm_group": {
            "arm_group_label": "Regnite group", 
            "description": "Patients who receive Regnite"
        }, 
        "brief_summary": {
            "textblock": "This study is to investigate the long-term safety and efficacy and the information on the\n      proper use of Regnite\u00ae under conditions of daily clinical use."
        }, 
        "brief_title": "Specified Drug Use-Results Survey of Regnite", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Restless Legs Syndrome", 
        "condition_browse": {
            "mesh_term": "Restless Legs Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start\n      and during the treatment.  The treatment period is scheduled to last 52 weeks in principle.\n      For patients completing or discontinuing the use of Regnite\u00ae within 52 weeks, follow up on\n      the withdrawal and rebound syndrome will be conducted up to 4 weeks of completion or\n      discontinuation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with moderate to severe idiopathic restless legs syndrome\n\n        Exclusion Criteria:\n\n          -  Patients with a history of hypersensitivity to any ingredients in Regnite or\n             gabapentin\n\n          -  Patients with severely impaired renal function (creatinine clearance of less than 30\n             mL/min)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with moderate to severe idiopathic restless legs syndrome"
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887613", 
            "org_study_id": "REG001"
        }, 
        "intervention": {
            "arm_group_label": "Regnite group", 
            "description": "oral", 
            "intervention_name": "Regnite", 
            "intervention_type": "Drug", 
            "other_name": "gabapentin enacarbil"
        }, 
        "intervention_browse": {
            "mesh_term": "Gabapentin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Gabapentin", 
        "lastchanged_date": "June 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Touhoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Specified Drug Use-Results Survey of Regnite", 
        "overall_contact": {
            "email": "clinicaltrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Use Central Contact", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety such as occurrence of adverse drug reactions and lab-tests", 
            "safety_issue": "No", 
            "time_frame": "Up to 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Restless Leg Syndrome score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at 52 weeks"
            }, 
            {
                "measure": "Clinical Global Impression", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at 52 weeks"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}